Samuel Kintz sold $82k of ELVN
PRESIDENT AND CEO at Enliven Therapeutics, Inc.. 5,000 shares at an average of $16.49, traded May 19, 2025, filed May 21, 2025.
Score components
- +25RoleCEO
- +9Trade size$82k at market
- 0Share of holdings soldSold 0.5% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-013992, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 19, 2025 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -5,000 | $16.49 | $82k | 972,892 | May 21, 2025 |
Related signals
Other insiders at Enliven Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 54Moderate | Enliven Therapeutics, Inc. | J. Scott Garland director | $607k 13,000 shares | -100% | |
| 13Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $252k 5,000 shares | -17% | |
| 21Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $303k 6,018 shares | -14% | |
| 25Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $1.4M 40,000 shares | -62% | |
| 4Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $139k 5,000 shares | -17% | |
| 33Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $1.2M 40,000 shares | -73% | |
| 49Moderate | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $296k 10,000 shares | -16% | |
| 40Moderate | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $1.2M 45,000 shares | -64% | |
| 15Weak | Enliven Therapeutics, Inc. | Richard A. Heyman director | $32k 1,230 shares | -5% | |
| 21Weak | Enliven Therapeutics, Inc. | Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER | $145k 5,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.